Par Drugs and Chemicals Ltd
NSE:PAR
Relative Value
The Relative Value of one
PAR
stock under the Base Case scenario is
213.89
INR.
Compared to the current market price of 90.29 INR,
Par Drugs and Chemicals Ltd
is
Undervalued by 58%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Multiples Across Competitors
PAR Competitors Multiples
Par Drugs and Chemicals Ltd Competitors
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| IN |
|
Par Drugs and Chemicals Ltd
NSE:PAR
|
1.1B INR | 1 | 8 | 4.3 | 5.4 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
944.6B USD | 14.5 | 45.8 | 30.9 | 32.9 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
585.1B USD | 6.2 | 21.8 | 15.2 | 18.6 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
262.8B CHF | 4.3 | 20.4 | 12 | 13.5 | |
| CH |
|
Novartis AG
SIX:NOVN
|
233.9B CHF | 5.3 | 21.5 | 13.3 | 17.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
223.2B GBP | 5.1 | 29.2 | 16.2 | 22.8 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
287.6B USD | 4.4 | 15.8 | 9.8 | 11.9 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD | 94 | -74.6 | 344.9 | 865 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 3.6 | 10.9 | 8 | 9.4 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
155.2B USD | 2.5 | 20 | 7.7 | 10.2 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
120.7B USD | 2.5 | 17.1 | 7.2 | 8.9 |